Compare Aventis Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs VENUS REMEDIES - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA VENUS REMEDIES SANOFI INDIA/
VENUS REMEDIES
 
P/E (TTM) x 41.7 -1.2 - View Chart
P/BV x 7.4 0.1 9,257.0% View Chart
Dividend Yield % 1.2 0.0 -  

Financials

 SANOFI INDIA   VENUS REMEDIES
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
VENUS REMEDIES
Mar-18
SANOFI INDIA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs6,840126 5,433.0%   
Low Rs4,63061 7,577.7%   
Sales per share (Unadj.) Rs1,203.1301.8 398.7%  
Earnings per share (Unadj.) Rs165.3-24.9 -664.5%  
Cash flow per share (Unadj.) Rs209.92.5 8,247.2%  
Dividends per share (Unadj.) Rs84.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs963.6293.3 328.6%  
Shares outstanding (eoy) m23.0312.34 186.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.80.3 1,538.6%   
Avg P/E ratio x34.7-3.8 -923.1%  
P/CF ratio (eoy) x27.336.7 74.4%  
Price / Book Value ratio x6.00.3 1,866.8%  
Dividend payout %50.80-   
Avg Mkt Cap Rs m132,0781,154 11,447.3%   
No. of employees `0003.30.9 356.9%   
Total wages/salary Rs m4,068393 1,034.9%   
Avg. sales/employee Rs Th8,393.84,026.1 208.5%   
Avg. wages/employee Rs Th1,232.4425.0 290.0%   
Avg. net profit/employee Rs Th1,153.0-331.8 -347.5%   
INCOME DATA
Net Sales Rs m27,7083,724 744.0%  
Other income Rs m89723 3,986.7%   
Total revenues Rs m28,6053,747 763.5%   
Gross profit Rs m6,235395 1,579.3%  
Depreciation Rs m1,027338 303.6%   
Interest Rs m7354 2.0%   
Profit before tax Rs m6,098-275 -2,215.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,29232 7,253.2%   
Profit after tax Rs m3,806-307 -1,240.1%  
Gross profit margin %22.510.6 212.3%  
Effective tax rate %37.6-11.5 -327.5%   
Net profit margin %13.7-8.2 -166.7%  
BALANCE SHEET DATA
Current assets Rs m15,9222,638 603.6%   
Current liabilities Rs m6,2352,305 270.5%   
Net working cap to sales %35.08.9 391.0%  
Current ratio x2.61.1 223.1%  
Inventory Days Days64135 47.0%  
Debtors Days Days2146 45.0%  
Net fixed assets Rs m7,5394,871 154.8%   
Share capital Rs m230123 186.4%   
"Free" reserves Rs m21,9623,496 628.3%   
Net worth Rs m22,1923,619 613.2%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m29,8397,509 397.4%  
Interest coverage x872.10.2 391,139.5%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.90.5 187.2%   
Return on assets %12.80.6 2,024.2%  
Return on equity %17.2-8.5 -202.2%  
Return on capital %27.51.6 1,738.9%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m7,5870-   
Fx outflow Rs m7,145517 1,383.3%   
Net fx Rs m442-517 -85.6%   
CASH FLOW
From Operations Rs m3,739514 726.9%  
From Investments Rs m-731-123 593.8%  
From Financial Activity Rs m-1,972-387 509.4%  
Net Cashflow Rs m1,0364 24,666.7%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 0.2 8,000.0%  
FIIs % 14.6 0.6 2,517.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 66.4 15.8%  
Shareholders   15,184 20,121 75.5%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   CIPLA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Over 400 Points Higher, Rising Gold Prices, and Top Cues in Focus Today(Pre-Open)

Indian share markets continued their momentum during closing hours yesterday and ended on a positive note today.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

CoronaVirus' Impact on Indian Markets - And One Stock With the Potential to Make Crores...(Profit Hunter)

Feb 7, 2020

Even as the experts come to grips with impact of Coronavirus contagion on Indian stocks and economy, here's a stock not just immune to macro threats, but with the potential to offer crores in the long term.

A Megatrend to Help You Find the Best Stocks of the Next Decade(The 5 Minute Wrapup)

Feb 12, 2020

Recent events have put climate change into the spotlight. Here's how you should play this megatrend...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 19, 2020 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - DISHMAN PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS